Accordingly, ANXA1 fragment Ac2-26 administration in vivo significantly reduces atherosclerotic lesion sizes and macrophage accumulation in an FPR2 dependent manner [103], and the delivery of nanoparticles containing the proresolving ANXA1 mimicking peptide Ac2-26 reduces experimental atherosclerosis in presence of a functional FPR2 [106]. The gene discussed is ANXA1; the disease is atherosclerosis.